Vnitr Lek 2014, 60(4):322-326

Fully absorbable drug eluting coronary stent: where do we stand in 2014?

Viktor Kočka*, Petr Toušek, Libor Lisa, Tomáš Buděšínský
III. interní - kardiologická klinika 3. LF UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Petr Widimský, DrSc., FESC, FACC

Coronary stent is routinely used in majority percutaneous coronary interventions for a long time. They have an important role, especially, in the first months after intervention. We can consider as a breakthrough point the development of stent which has ability to absorb in intervened artery after a few years. The review presents current techniques of fully absorbable coronary stents and also provides clinical trials and experiences available in 2014. The article continues with discussion between supporters and opponents of this new technique, but definitive conclusion can't be done yet. The authors conclude the review with their own opinion. There are many encouraging data in patients with good clinical outcome after implantation of absorbable stents in more than 10 years follow-up.

Keywords: absorbable stent; acute myocardial infarction; coronary stent; percutaneous coronary intervention

Received: January 30, 2014; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kočka V, Toušek P, Lisa L, Buděšínský T. Fully absorbable drug eluting coronary stent: where do we stand in 2014? Vnitr Lek. 2014;60(4):322-326.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316(12): 701-706. Go to original source... Go to PubMed...
    2. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331(8): 489-495. Go to original source... Go to PubMed...
    3. Widimsky P, Groch L, Zelizko M et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21(10): 823-831. Go to original source... Go to PubMed...
    4. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-1780. Go to original source... Go to PubMed...
    5. Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102(4): 399-404. Go to original source... Go to PubMed...
    6. Ormiston JA, Webster MW, Armstrong G First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69(1): 128-131. Go to original source... Go to PubMed...
    7. Onuma Y, Serruys PW, Perkins LE et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010; 122(22): 2288-2300. Go to original source... Go to PubMed...
    8. Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013; 381(9869): 836-844. Go to original source... Go to PubMed...
    9. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371 (9616): 899-907. Go to original source... Go to PubMed...
    10. Dudek D, Onuma Y, Ormiston JA et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012; 7(9): 1060-1061. Go to original source... Go to PubMed...
    11. Onuma Y, Serruys PW, Gomez J et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011; 78(1): 3-12. Go to original source... Go to PubMed...
    12. Gomez-Lara J, Garcia-Garcia HM, Onuma Y et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010; 3(11): 1190-1198. Go to original source... Go to PubMed...
    13. Garcia-Garcia HM, Gonzalo N, Pawar R et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 2009; 4(4): 443-448. Go to original source... Go to PubMed...
    14. Bruining N, de Winter S, Roelandt JR et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv 2010; 3(4): 449-456. Go to original source... Go to PubMed...
    15. Brugaletta S, Gomez-Lara J, Bruining N et al. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. EuroIntervention 2012; 8(3): 352-358. Go to original source... Go to PubMed...
    16. Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58(15): 1578-1588. Go to original source... Go to PubMed...
    17. Gomez-Lara J, Radu M, Brugaletta S et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv 2011; 4(9): 992-1001. Go to original source... Go to PubMed...
    18. Muramatsu T, Onuma Y, Garcia-Garcia HM et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv 2013; 6(3): 247-257. Go to original source... Go to PubMed...
    19. Wiebe J, Mollmann H, Most A et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 2014; 103(2): 141-148. Go to original source... Go to PubMed...
    20. Kocka V, Lisa L, Tousek P et al. ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. Eur Heart J 2013; 34(27): 2073. Go to original source... Go to PubMed...
    21. Kajiya T, Liang M, Sharma RK et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013; 9(4): 501-504. Go to original source... Go to PubMed...
    22. Kocka V, Maly M, Tousek P et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study "Prague 19". Eur Heart J 2014; 35(12): 787-794. Go to original source... Go to PubMed...
    23. Diletti R, Karanasos A, Muramatsu T et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014; 35(12): 777-786. Go to original source... Go to PubMed...
    24. La Manna A, Ohno Y, Attizzani GF et al. Successful retrograde recanalization of chronic total coronary occlusion with multiple bioresorbable vascular scaffolds (full polymer jacket): initial experience and rationale. Eur Heart J 2013; 34(37): 2925. Go to original source... Go to PubMed...
    25. Grundeken MJ, Kraak RP, de Bruin DM et al. Three-dimensional optical coherence tomography evaluation of a left main bifurcation lesion treated with ABSORB(R) bioresorbable vascular scaffold including fenestration and dilatation of the side branch. Int J Cardiol 2013; 168(3): e107-e108. Go to original source... Go to PubMed...
    26. Ong PJ, Jafary FH, Ho HH "First-in-man" use of bioresorbable vascular scaffold in saphenous vein graft. EuroIntervention 2013; 9(1): 165. Go to original source... Go to PubMed...
    27. Nieman K, Serruys PW, Onuma Y et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol 2013; 62(19): 1813-1814. Go to original source... Go to PubMed...
    28. Okamura T, Onuma Y, Garcia-Garcia HM et al. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. JACC Cardiovasc Interv 2010; 3(8): 836-844. Go to original source... Go to PubMed...
    29. Okamura T, Serruys PW, Regar E Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010; 31(17): 2179. Go to original source... Go to PubMed...
    30. Farooq V, Onuma Y, Radu M et al. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention 2011; 7(3): 386-399. Go to original source... Go to PubMed...
    31. Nishio S, Kosuga K, Igaki K et al. Long-Term (10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012; 125(19): 2343-2353. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.